Consistent with previous reports describing tumor-derived EVs [27,28], immune checkpoints CD47 and CD274/PD-L1, and key regulators of myeloid differentiation (e.g., TRIB1, SOCS3, STAT3) were upregulated in EwS EV-treated cells compared to control, with TC32 EVs generally eliciting stronger effect (Figure 4D). Here, SOCS3 is linked to neoplasm.